The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study Multiparameter flow cytometry (MFC) was used to assess MRD after induction ...

The UAB Flow Cytometry Lab is home to a staff of medical laboratory professionals who perform complex testing using state-of-the-art flow cytometry equipment. This testing, through research, education ...

Your doctor tells you your multiple myeloma is in remission. But what exactly does that mean? The first thing to understand is that being in remission is not the same thing as being cured. The ...

The last decade has seen a revolution in cancer immunotherapy. The demand from doctors, researchers, and pharmaceutical companies for more precise results with high sensitivity and high-quality ...

Level of circulating endothelial cells as new biomarker in patients with multiple myeloma, treated with bortezomib-pegylated liposomal doxorubicin-dexamethasone combination No significant financial ...

Multiple myeloma (MM) is a cancer of plasma cells that is associated with low blood counts, bone and calcium disorders and infections. Despite advances in treatment in the past decade, the number of ...

Using tests to identify minimal residual disease may help determine how much treatment patients with multiple myeloma require. The landscape of multiple myeloma is changing, which is now bringing in ...